Originally published on marketersmedia.com
Kevin Dalby, Austin-based professor of chemical biology and medicinal chemistry in the College of Pharmacy and Department of Oncology at The University of Texas, has released his latest study - "JNK Signaling in Stem Cell Self-Renewal and Differentiation."
AUSTIN, Texas - May 8, 2020 /MarketersMedia/ — Kevin Dalby, professor of chemical biology and medicinal chemistry in the College of Pharmacy and Department of Oncology at The University of Texas, has released his latest review - "JNK Signaling in Stem Cell Self-Renewal and Differentiation."
The review investigates C-JUN N-terminal kinases (JNKs), which are evolutionarily conserved kinases that mediate cell responses to different types of extracellular stress insults. They play roles in cell proliferation, programmed cell death, tumorigenesis, the progression of several types of malignancies, and crucially, the regulation of traits of cancer stem cells.
This review describes the functions of the JNK signaling pathway in self-renewal and differentiation. It also analyzes the current knowledge of JNK signaling in cancer stem cells. The ultimate goal is to provide a better understanding of JNK signaling as an essential regulator of stemness, to provide a basis for the creation of regenerative medicine and therapeutic strategies against malignant tumors.
Kevin Dalby is part of a team of scientists that are working tirelessly to discovering new medicines to treat cancer.
"Work in my laboratory converges on mechanisms in cancer where we discover new cell signaling processes and develop new molecular tools to aid our understanding. Our studies have elucidated new mechanisms by which cancer cells send communications, and identified molecules with novel mechanisms of action to inhibit them," he elaborates.
This review is only his latest in a long line of research in his capacity as a professor of chemical biology and medicinal chemistry in the College of Pharmacy and Department of Oncology at The University of Texas in Austin. Dr. Kevin Dalby is also the director of The Targeted Therapeutic Drug Discovery & Development Program. His goal is to assist cancer scientists and clinicians in the early phases of cancer drug discovery.
Not only does he work at developing tools to eradicate cancer, but he is also a professor teaching students in the professional Pharm.D. program.
Dr. Dalby says that his ultimate purpose is, "To continue to train the next generation of scientists to go out there and do great things. Additionally, to make contributions that will bring us closer to finding cures for some of the more challenging cancers that society faces."
About Kevin Dalby
Dr. Kevin Dalby is a professor of chemical biology and medicinal chemistry, currently working on cancer drug discovery. At the College of Pharmacy at The University of Texas, he is examining the mechanisms of nature and cancer to develop new treatments, and teaching and motivating students to conduct research. Dalby is optimistic about the future of cancer treatments.
We just sent you an email. Please click the link in the email to confirm your subscription!